Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Dana A. Elfin
Jan. 22 — Acorda Therapeutics Inc. and Par Pharmaceutical Inc. have settled patent litigation over Par's application to make a generic of Acorda's multiple sclerosis treatment Ampyra (dalfampridine extended release tablets) before patents covering the drug expire.
Under a consent judgment entered in the U.S. District Court for the District of Delaware Jan. 21, Par agreed that the four Acorda patents at issue were valid and enforceable and that its proposed generic would infringe those patents.
The patents at issue, U.S. Patent Nos. 8,007,826 (the '826 patent), 8,354,437 (the '437 patent), 8,440,703 (the '703 patent), and 8,663,685 (the '685 patent), have expiration dates from Jan. 18, 2025, to May 26, 2027, according to the Food and Drug Administration's Orange Book.
Par agreed not to market generic versions of Ampyra until a license to the patents, provided in the parties's settlement agreement, becomes effective.
Ampyra is used to help people walk when they have multiple sclerosis, a disorder that attacks both the central nervous and immune systems. Acorda's patents cover a dosing regimen to make sure the drug works.
In 2015, Kyle Bass's Coalition for Affordable Drugs challenged two of Acorda Therapeutics's Amypra patents, the ‘685 patent and the ‘437 patent, at the Patent and Trademark Office. Bass argued that the Acorda patents simply cobbled together what scientists already knew about Ampyra's active ingredient and the optimal dosages. But the Patent Trial and Appeal Board ultimately rejected the petitions (13 PLIR 1253, 8/28/15).
Acorda is based in Ardsley, N.Y. Par is based in Chestnut Ridge, N.Y.
The firms of Kaye Scholer LLP in Washington and New York and Morris Nichols Arsht & Tunnell LLP in Wilmington, Del., represented Acorda.
The firms of Arent Fox LLP in Washington and Young Conaway Stargatt & Taylor LLP in Wilmington, Del., represented Par.
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)